1. Overview of CBD OG Kush (1:15)
CBD OG Kush is a hybrid cannabis strain that has high levels of both CBD and THC. This makes it a popular choice for medical users who want the benefits of both cannabinoids. The CBD to THC ratio is 1:15, meaning that there is 15 times more CBD than THC in this strain. This makes it a very good option for those who want the medicinal benefits of cannabis without the high.
2. Aroma, flavor and appearance
CBD OG Kush has a citrusy, earthy aroma with hints of diesel fuel. The flavor is similar, with a sour lemon taste and a pungent aftertaste. The buds are dense and green, with orange hairs and a frosty coating of trichomes.
3. Growing this strain
CBD OG Kush is a relatively easy strain to grow, and it is suitable for both indoor and outdoor cultivation. It has a high yield and is resistant to many common pests and diseases. The flowering time is 9-10 weeks, and plants usually reach a height of around 2 meters.
4. Effects on mind and body
The effects of CBD OG Kush are very well balanced. The high levels of CBD make it a very relaxing strain, while the THC provides a gentle uplifting effect. This makes it a good choice for those who want to relax without feeling couch-locked. It can also help to relieve pain, stress, anxiety and inflammation.
5. Medical benefits
CBD OG Kush is a popular choice for medical cannabis users due to its high levels of both CBD and THC. The CBD helps to relieve pain, anxiety and inflammation, while the THC provides a gentle uplifting effect. This makes it a good strain for those who want to relax without feeling couch-locked. It can also help to improve appetite and relieve nausea.
6. Negative side effects
CBD OG Kush is a very well-tolerated strain, but some people may experience dry mouth or eyes. This is easily alleviated by drinking plenty of water and using eye drops if necessary. Some people may also experience dizziness or paranoia when smoking this strain, so it is best to start with a small dose and increase it gradually. as needed.
There are no reviews yet.